Gruppo Oncologico del Nord-Ovest
- Country
- 🇮🇹Italy
- Ownership
- Private
- Established
- 1987-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://gonogroup.org/
Denosumab In Ebv Nasopharyngeal Carcinoma As A Model For RankMediated Immunologic Modulation Of Virus-Related Tumours
- Conditions
- Nasopharyngeal CarcinomaEBV Related Carcinoma
- Interventions
- Drug: Chemotherapy as clinical standard of care
- First Posted Date
- 2019-04-23
- Last Posted Date
- 2020-02-17
- Lead Sponsor
- Gruppo Oncologico del Nord-Ovest
- Target Recruit Count
- 45
- Registration Number
- NCT03923842
- Locations
- 🇮🇹
ASST degli Spedali Civili di Brescia, Brescia, Italy
🇮🇹Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
Immunotherapy In Locally Advanced Rectal Cancer
- Conditions
- Colon Rectal Cancer
- Interventions
- First Posted Date
- 2019-02-26
- Last Posted Date
- 2023-10-19
- Lead Sponsor
- Gruppo Oncologico del Nord-Ovest
- Target Recruit Count
- 101
- Registration Number
- NCT03854799
- Locations
- 🇮🇹
Policlinico Gemelli, Rome, Italy
Targeting the Tumor Microenvironment in R/M SCCHN
- First Posted Date
- 2019-02-18
- Last Posted Date
- 2020-03-03
- Lead Sponsor
- Gruppo Oncologico del Nord-Ovest
- Target Recruit Count
- 71
- Registration Number
- NCT03844763
- Locations
- 🇮🇹
AO Santa Croce e Carle di Cuneo, Cuneo, Italia/cuneo, Italy
🇮🇹Azienda Ospedaliera S. Croce E Carle Di Cuneo - Cuneo (Cn) Oncologia Medica, Cuneo, Italy
FOLFOXIRI + Bev + Atezo vs FOLFOXIRI + Bev as First-line Treatment of Unresectable Metastatic Colorectal Cancer Patients
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2018-10-26
- Last Posted Date
- 2023-10-12
- Lead Sponsor
- Gruppo Oncologico del Nord-Ovest
- Target Recruit Count
- 218
- Registration Number
- NCT03721653
- Locations
- 🇮🇹
Francesca Vannini, Pisa, Italia, Italy
First Line mFOLFOXIRI + PANITUMUMAB vs mFOLFOX + PANITUMUMAB IN RAS AND BRAF WT METASTATIC COLORECTAL CANCER PATIENTS
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2017-07-27
- Last Posted Date
- 2023-01-05
- Lead Sponsor
- Gruppo Oncologico del Nord-Ovest
- Target Recruit Count
- 435
- Registration Number
- NCT03231722
- Locations
- 🇮🇹
Fondazione IRCCS Istituto Oncologico Veneto, Padova, Italy
🇮🇹A.O. Universitaria Pisana - Pisa (Pi) Oncologia Medica, Pisa, Italy
🇮🇹Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy
Study of I Line FOLFOX + Panitumumab vs 5FU + Panitumumab in RAS and BRAF WT Metastatic Colorectal Cancer Elderly Patients
- Conditions
- Elderly Metastatic Colorectal Cancer Patients
- Interventions
- First Posted Date
- 2016-09-16
- Last Posted Date
- 2020-05-12
- Lead Sponsor
- Gruppo Oncologico del Nord-Ovest
- Target Recruit Count
- 180
- Registration Number
- NCT02904031
- Locations
- 🇮🇹
Istituto Oncologico Veneto IRCCS, Padua, Italy
Folfoxiri Plus Bev Followed by Reintroduction of Folfoxiri Plus Bev at Progression Versus Folfox Plus Bev Followed by Folfiri Plus Bev in mCRC
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2015-01-15
- Last Posted Date
- 2020-02-05
- Lead Sponsor
- Gruppo Oncologico del Nord-Ovest
- Target Recruit Count
- 654
- Registration Number
- NCT02339116
- Locations
- 🇮🇹
Polo Oncologico - AOUP, Pisa, PI, Italy
Induction Chemoterapy With Folfoxiri Plus Cetuxumab in Unresectable Colorectal Cancer Patient
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- Other: folfoxiri+cetuximab+surgery+bevacizumabOther: folfoxiri+cetuximab+surgery+cetuximab
- First Posted Date
- 2014-11-20
- Last Posted Date
- 2015-03-12
- Lead Sponsor
- Gruppo Oncologico del Nord-Ovest
- Target Recruit Count
- 143
- Registration Number
- NCT02295930
- Locations
- 🇮🇹
A.O.Universitaria Policlinico S.Orsola-Malpighi Di Bologna (Oncologia Medica), Bologna, Italy
🇮🇹Istituto Ospedaliero Fondazione Poliambulanza Di Brescia - Brescia (Bs) Oncologia Medica, Brescia, Italy
🇮🇹Ospedale Civile Ss. Antonio E Biagio Di Alessandria - Alessandria (Al) Oncologia Medica, Alessandria, Italy
Cetuximab Rechallenge in Irinotecan-pretreated mCRC, KRAS, NRAS and BRAF Wild-type Treated in 1st Line With Anti-EGFR Therapy (CRICKET).
- First Posted Date
- 2014-11-20
- Last Posted Date
- 2018-02-15
- Lead Sponsor
- Gruppo Oncologico del Nord-Ovest
- Target Recruit Count
- 27
- Registration Number
- NCT02296203
- Locations
- 🇮🇹
Azienda Ospedaliero Universitaria Di Parma - U.O.Oncologia Medica, Parma, Italy
🇮🇹A.O. Universitaria S.Maria Della Misericordia Di Udine, Udine, Italy
🇮🇹Azienda Policlinico Umberto I - Oncologia Medica, Roma, Italy
FOLFOXIRI Plus Panitumumab In Kras and Braf Wild-Type Metastatic Colorectal Cancer
- Conditions
- Metastatic Colo-rectal Cancer
- Interventions
- Drug: FOLFOXIRI + Panitumumab
- First Posted Date
- 2011-05-24
- Last Posted Date
- 2015-03-11
- Lead Sponsor
- Gruppo Oncologico del Nord-Ovest
- Target Recruit Count
- 37
- Registration Number
- NCT01358812
- Locations
- 🇮🇹
P.O. Zona Aretina - Ospedale S. Donato Di Arezzo, Arezzo, Italy
🇮🇹IRCCS Ospedale San Raffaele, Milano, Italy
🇮🇹Istituto Nazionale Per La Ricerca Sul Cancro, Genova, Italy